Clinical Report: Gummies Good for the Gums

Overview

A double-blind randomized trial demonstrated that gummies containing heat-inactivated Lactiplantibacillus pentosus ONRICb0240 significantly reduced gingival inflammation in adults. Participants not taking NSAIDs showed a notable decrease in bleeding on probing and improved gingival index scores over six weeks.

Background

Gingival inflammation is a common oral health issue that can lead to more severe periodontal diseases if left untreated. Traditional treatments focus on mechanical cleaning and oral hygiene, but adjunctive therapies like probiotics and postbiotics are gaining interest for their potential benefits. This study explores the efficacy of a postbiotic gummy in managing gingival inflammation, providing insights into novel treatment options.

Data Highlights

Key Findings

• 116 adults with gingival inflammation participated in the trial.
• Participants chewed gummies containing heat-inactivated Lactiplantibacillus pentosus ONRICb0240 twice daily for 6 weeks.
• Significant reduction in bleeding on probing from 17.6% to 12.3% in the treatment group.
• Improvement in gingival index scores was observed, while other periodontal measures remained unchanged.
• Participants with a BMI of at least 22 kg/m² showed the strongest responses.
• No safety concerns were reported during the trial.

Clinical Implications

The findings suggest that postbiotic gummies may serve as a beneficial adjunct to standard oral hygiene practices for managing gingival inflammation. Clinicians may consider recommending such products to patients with mild gingival issues, particularly those who struggle with traditional treatment methods.

Conclusion

This study highlights the potential of postbiotics as a novel approach to managing gingival inflammation, warranting further research to establish long-term efficacy and integration into clinical practice.

Related Resources & Content

1. Institute of Science Tokyo, Journal of Periodontology, 2026 -- Consuming heat-inactivated Lactiplantibacillus pentosus ONRICb0240-containing postbiotics reduces gingival inflammation: A double-blind randomized clinical trial
2. Otsuka Pharmaceutical, News Release, 2026 -- 乳酸菌ONRICb0240の歯肉炎への効果を確認東京科学大学との共同研究
3. EFP, Treatment of stage I–III periodontitis—The EFP S3 level clinical practice guideline, PMC, 2026
4. conexiant — Medical Oddities: Chew on This Cancer Prevention Idea
5. Infection — Decreased SARS-CoV-2 Viral Presence in Exhaled Breath Following Use of Antiseptic Chewing Gum: A Preliminary Study
6. conexiant — Medical Oddities: Disney, But Make It Clinical
7. ADA News — Forsyth Friday: New antibodies may aid diagnosis of gum-linked systemic diseases
8. Periodontitis | American Dental Association
9. About Periodontal (Gum) Disease | Oral Health | CDC
10. Treatment of stage I–III periodontitis—The EFP S3 level clinical practice guideline - PMC
11. EFP Clinical GuidelineTreatment of stage I-III per
12. 乳酸菌ONRICb0240の歯肉炎への効果を確認東京科学大学との共同研究　オーラルケアに新たな期待｜2026年4月21日｜ニュースリリース｜大塚製薬
13. Consuming heat‐inactivated Lactiplantibacillus pentosus ONRICb0240‐containing postbiotics reduces gingival inflammation: A double‐blind randomized clinical trial | Journal of Periodontology | DeepDyve
14. Consuming heat-inactivated Lactiplantibacillus pentosus ONRICb0240-containing postbiotics reduces gingival inflammation: a double-blind randomized clinical trial
15. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics - PMC
16. Oral probiotic Weissella cibaria improves halitosis and reduces periodontal pathogens: a randomized, double-blind, placebo-controlled trial | BMC Oral Health | Springer Nature Link
17. Probiotics in the non-surgical treatment of periodontitis: a systematic review and network meta-analysis | BMC Oral Health | Full Text